← Leaderboards
Patrick H Nachman
University Of North Carolina Chapel Hill
$4,212,672
Attributed
$4,987,671
Total exposure
10
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $500K · FY2008–25$500K$375K$250K$125K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,987,671 · 10
By mechanism
P01$2,083,688 · 3
U01$1,549,999 · 1
M01$1,353,984 · 6
Top collaborators
- Maria Luiza A Caramori4 shared
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Ronald J Falk$26,386,981
- Susan L Hogan$3,706,530
- Mary A Dooley$3,689,855
- William R Meyer$1,559,955
- Gloria A Preston$2,531,436
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectGlomerulonephritisClinical ResearchHuman Therapy EvaluationNeutrophilVasculitisAutoantibodyProteinuriaKidney TransplantationPlacebosClinical TrialsMorbidity - Disease RateResearch PersonnelMolecularSuccessAutoimmunityAntileukocyte IsoantibodyMortalityLosartanNoninsulin Dependent Diabetes MellitusDiabetes Mellitus TherapyCreatinineDiabetic NephropathyHypoglycemic Agents
Grant awards (36)
Minnesota Precision Medicine CKD & Resilient Diabetes Recruiting Site: Engagement, Enrollment & Ethics$499,999
U01 · FY2025 · DK · contact PI
Minnesota Precision Medicine CKD & Resilient Diabetes Recruiting Site: Engagement, Enrollment & Ethics$100,000
U01 · FY2024 · DK · contact PI
Minnesota Precision Medicine CKD & Resilient Diabetes Recruiting Site: Engagement, Enrollment & Ethics$450,000
U01 · FY2023 · DK · contact PI
Minnesota Precision Medicine CKD & Resilient Diabetes Recruiting Site: Engagement, Enrollment & Ethics$500,000
U01 · FY2022 · DK · contact PI
Clinical applications to main durable remission, minimize relapse and prevent infection in ANCA GN.$257,141
P01 · FY2019 · DK · contact PI
Clinical applications to main durable remission, minimize relapse and prevent infection in ANCA GN.$257,141
P01 · FY2018 · DK · contact PI
Clinical applications to main durable remission, minimize relapse and prevent infection in ANCA GN.$257,141
P01 · FY2016 · DK · contact PI
Clinical applications to main durable remission, minimize relapse and prevent infection in ANCA GN.$257,141
P01 · FY2015 · DK · contact PI
Translation of Knowledge on the Pathogenesis of ANCA Disease into Novel$219,374
P01 · FY2010 · DK · contact PI
CLINICAL TRIAL: RITUXIMAB IN THE TREATMENT OF IDIOPATHIC MEMBRANOUS NEPHROPATHY$230
M01 · FY2008 · RR · contact PI
Cyclophosphamide-Related Urothelial Tumor Evaluation$1,415
M01 · FY2004 · RR
MOLECULAR BIOLOGY OF ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES$190,747
M01 · FY2002 · RR
STUDY TO EVALUATE THE RENAL PROTECTIVE EFFECTS OF LOSARTAN$190,747
M01 · FY2002 · RR
Anti-myeloperoxidase autoantibody response$167,150
P01 · FY2002 · DK
Anti-myeloperoxidase autoantibody response$167,150
P01 · FY2002 · DK
Anti-myeloperoxidase autoantibody response$167,150
P01 · FY2002 · DK
STUDY TO EVALUATE THE RENAL PROTECTIVE EFFECTS OF LOSARTAN$294,555
M01 · FY2001 · RR
MOLECULAR BIOLOGY OF ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES$294,555
M01 · FY2001 · RR
MOLECULAR BIOLOGY OF ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES$190,747
M01 · FY2001 · RR
STUDY TO EVALUATE THE RENAL PROTECTIVE EFFECTS OF LOSARTAN$190,747
M01 · FY2001 · RR
Anti-myeloperoxidase autoantibody response$167,150
P01 · FY2001 · DK
Anti-myeloperoxidase autoantibody response$167,150
P01 · FY2000 · DK
MOLECULAR BIOLOGY OF ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES$241
M01 · FY2000 · RR
H5G1.1-MAB ON THE REDUCTION OF PROTEINUREA IN GLOMERULOPATHY$0
M01 · FY2000 · RR
H5G1.1-MAB ON THE REDUCTION OF PROTEINUREA IN GLOMERULOPATHY$0
M01 · FY2000 · RR
IDEC-131 IN PTS W/ ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2000 · RR
IDEC-131 IN PTS W/ ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2000 · RR
IDEC-131 IN PTS W/ ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS$0
M01 · FY2000 · RR
MOLECULAR BIOLOGY OF ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES$0
M01 · FY2000 · RR
MOLECULAR BIOLOGY OF ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES$0
M01 · FY2000 · RR
MOLECULAR BIOLOGY OF ANTINEUTROPHIL CYTOPLASMIC AUTOANTIBODIES$0
M01 · FY2000 · RR
EFFECTS OF LOSARTAN IN PTS W/ NIDDM &NEPHROPATHY$0
M01 · FY2000 · RR
EFFECTS OF LOSARTAN IN PTS W/ NIDDM &NEPHROPATHY$0
M01 · FY2000 · RR
EFFECTS OF LOSARTAN IN PTS W/ NIDDM &NEPHROPATHY$0
M01 · FY2000 · RR
EFFECTS OF LOSARTAN IN PTS W/ NIDDM &NEPHROPATHY$0
M01 · FY2000 · RR
H5G1.1-MAB ON THE REDUCTION OF PROTEINUREA IN GLOMERULOPATHY$0
M01 · FY2000 · RR